Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H16BrF3N4O |
Molecular Weight | 429.234 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C1=CN=C(C=C1)N2CC[C@H](C2)NC(=O)NC3=CC=CC=C3Br
InChI
InChIKey=JYILLRHXRVTRSH-GFCCVEGCSA-N
InChI=1S/C17H16BrF3N4O/c18-13-3-1-2-4-14(13)24-16(26)23-12-7-8-25(10-12)15-6-5-11(9-22-15)17(19,20)21/h1-6,9,12H,7-8,10H2,(H2,23,24,26)/t12-/m1/s1
Molecular Formula | C17H16BrF3N4O |
Molecular Weight | 429.234 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
SB-705498 is a selective vanilloid receptor-1 (VR1/TRPV1) antagonist developed by GlaxoSmithKline. The drug was tested in phase II of clinical trials for the treatment of pain (dental, rectal, in migraine) and rhinitis/cough. The development of the drug has been terminated by unknown reason (SB-705498 is no longer in GSK pipeline).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17392405 |
3.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
196.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23909699 |
12 mg 2 times / day multiple, nasal dose: 12 mg route of administration: Nasal experiment type: MULTIPLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.18 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17659837 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
86.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23909699 |
12 mg single, nasal dose: 12 mg route of administration: Nasal experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3416.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23909699 |
12 mg 2 times / day multiple, nasal dose: 12 mg route of administration: Nasal experiment type: MULTIPLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
42.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17659837 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
903.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23909699 |
12 mg single, nasal dose: 12 mg route of administration: Nasal experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
54.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17659837 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. | 2006 Jun 15 |
|
Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. | 2007 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01424514
Non Allergic Rhinitis: 12mg intra-nasal SB-705498 once daily. Chronic Cough: take 400 or 600mg orally.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21951314
The pharmacological activity of SB-705498 was characterized on HEK293 cells expressing the human TRPV1, using fluorometric calcium imaging. The cells were treated with different concentrations (10(-5)-10(-10) M) of the drug for 1 min or with 1uM for 30 min. The IC50 for the inhibition of 20 nM capsaicin-induced responses was estimated as 46 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:55:49 GMT 2023
by
admin
on
Sat Dec 16 02:55:49 GMT 2023
|
Record UNII |
T74V9O0Y2W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
T74V9O0Y2W
Created by
admin on Sat Dec 16 02:55:49 GMT 2023 , Edited by admin on Sat Dec 16 02:55:49 GMT 2023
|
PRIMARY | |||
|
SB-705498
Created by
admin on Sat Dec 16 02:55:49 GMT 2023 , Edited by admin on Sat Dec 16 02:55:49 GMT 2023
|
PRIMARY | |||
|
DTXSID20198236
Created by
admin on Sat Dec 16 02:55:49 GMT 2023 , Edited by admin on Sat Dec 16 02:55:49 GMT 2023
|
PRIMARY | |||
|
9910486
Created by
admin on Sat Dec 16 02:55:49 GMT 2023 , Edited by admin on Sat Dec 16 02:55:49 GMT 2023
|
PRIMARY | |||
|
300000042476
Created by
admin on Sat Dec 16 02:55:49 GMT 2023 , Edited by admin on Sat Dec 16 02:55:49 GMT 2023
|
PRIMARY | |||
|
501951-42-4
Created by
admin on Sat Dec 16 02:55:49 GMT 2023 , Edited by admin on Sat Dec 16 02:55:49 GMT 2023
|
PRIMARY | |||
|
DB11883
Created by
admin on Sat Dec 16 02:55:49 GMT 2023 , Edited by admin on Sat Dec 16 02:55:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL207433
Created by
admin on Sat Dec 16 02:55:49 GMT 2023 , Edited by admin on Sat Dec 16 02:55:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |